Informations générales (source: ClinicalTrials.gov)
Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells
Interventional
Phase 2/Phase 3
Celgene (Voir sur ClinicalTrials)
juillet 2018
novembre 2036
26 juin 2025
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for
all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy
participating in a previous Celgene sponsored or Celgene alliance partner sponsored
study.
Participants who received at least one infusion of GM T cells will be asked to enroll in
this LTFU protocol upon either premature discontinuation from, or completion of the prior
parent treatment protocol.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Vincent RIBRAG | 10/06/2024 12:26:35 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| AP-HP - Hôpital Henri Mondor-Albert Chenevier | Karim BELHADJ-MERZOUG, Site 09211 | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Hospitalier Lyon-Sud - 69495 - Pierre-Benite CEDEX - France | Herve Ghesquieres, Site 09201 | Contact (sur clinicalTrials) | |||
| Centre Hospitalier Universitaire (CHU) de Bordeaux - Hopital Haut-Leveque - 33600 - Pessac - France | Cyrille Hulin, Site 09210 | Contact (sur clinicalTrials) | |||
| CHRU de Lille France - 59037 - Lille Cedex - France | Ibrahim YAKOUB-AGHA, Site 09202 | Contact (sur clinicalTrials) | |||
| Chu Hotel Dieu - 44093 - Nantes Cedex 01 - France | Philippe Moreau, Site 09401 | Contact (sur clinicalTrials) | |||
| CHU La Miletrie - 86021 - Poitiers Cedex - France | xavier leleu, Site 09203 | Contact (sur clinicalTrials) | |||
| CHU Montpellier - Hôpital Saint Eloi - 34295 - Montpellier CEDEX 5 - France | Guillaume Cartron, Site 09206 | Contact (sur clinicalTrials) | |||
| Hopital Saint Louis - 75010 - Paris - France | Bertrand Arnulf, Site 09204 | Contact (sur clinicalTrials) | |||
| Hospital Saint Louis - 75475 - Paris - France | Catherine Thieblemont, Site 09207 | Contact (sur clinicalTrials) | |||
| Institut Universitaire du Cancer de Toulouse - Oncopole - 31059 - Toulouse CEDEX 9 - France | Aurore Perrot, Site 09205 | Contact (sur clinicalTrials) | |||
| Local Institution - 09400 - 13009 - Marseille Cedex 9 - France | Contact (sur clinicalTrials) | ||||
| Local Institution - 09600 - 75935 - Paris - France | Contact (sur clinicalTrials) | ||||
| Local Institution - 09601 - 69008 - Lyon - France | Contact (sur clinicalTrials) | ||||
| Local Institution - 09602 - 13385 - Marseille Cedex 9 - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
- Received at least one gene-modified (GM) T-cell infusion in a previous Celgene
sponsored or Celgene alliance partner-sponsored trial, and have discontinued, or
completed the post-treatment follow-up period in the parent treatment protocol, as
applicable.
- Must understand and voluntarily sign an Informed Consent Form/Informed Assent Form
prior to any study-related assessments/procedures being conducted.
- Received at least one gene-modified (GM) T-cell infusion in a previous Celgene
sponsored or Celgene alliance partner-sponsored trial, and have discontinued, or
completed the post-treatment follow-up period in the parent treatment protocol, as
applicable.
- Must understand and voluntarily sign an Informed Consent Form/Informed Assent Form
prior to any study-related assessments/procedures being conducted.
Not Applicable
Other protocol-defined inclusion/exclusion criteria apply